Archimed to Buy Esperion Therapeutics for Up to $1.1 Billion

Dow Jones

May 01

By Robb M. Stewart

Healthcare-focused investment firm Archimed is buying commercial-stage biopharmaceutical company Esperion Therapeutics for as much as $1.1 billion.

Esperion said Friday it has reached a definitive agreement that will see funds managed by Archimed pay shareholders $3.16 a share in cash, and offer the right to participate in milestone payments of up to $100 million tied to future sales performance. The upfront cash consideration represents a premium of 58% to Esperion's closing price a day earlier.

Esperion, which was founded in 2008, is focused on bringing new medicines to market and offers solutions to combat the risk of cardiovascular disease.

Chief Executive Sheldon Koenig said Archimed's acquisition offers Esperion shareholders with attractive and immediate upfront value while preserving the opportunity to see additional upside tied to future growth of the company's core cardiometabolic products.

Esperion's board unanimously approved the transaction and is recommending that shareholders vote their shares to approve the deal.

When the takeover is completed, Esperion will become a privately held company and its shares will no longer be listed on Nasdaq. The stock was halted in premarket trading.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

May 01, 2026 07:29 ET (11:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2632812611"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2632812611\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2632812611?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 19:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632812611","market":"hk","top_or_hot":-1,"title":"Archimed to Buy Esperion Therapeutics for Up to $1.1 Billion","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Healthcare-focused investment firm Archimed is buying commercial-stage biopharmaceutical company Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for as much as $1.1 billion. \n</p>\n<p>\n  Esperion said Friday it has reached a definitive agreement that will see funds managed by Archimed pay shareholders $3.16 a share in cash, and offer the right to participate in milestone payments of up to $100 million tied to future sales performance. The upfront cash consideration represents a premium of 58% to Esperion's closing price a day earlier. \n</p>\n<p>\n  Esperion, which was founded in 2008, is focused on bringing new medicines to market and offers solutions to combat the risk of cardiovascular disease. \n</p>\n<p>\n  Chief Executive Sheldon Koenig said Archimed's acquisition offers Esperion shareholders with attractive and immediate upfront value while preserving the opportunity to see additional upside tied to future growth of the company's core cardiometabolic products. \n</p>\n<p>\n  Esperion's board unanimously approved the transaction and is recommending that shareholders vote their shares to approve the deal. \n</p>\n<p>\n  When the takeover is completed, Esperion will become a privately held company and its shares will no longer be listed on Nasdaq. The stock was halted in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 01, 2026 07:29 ET (11:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Archimed to Buy Esperion Therapeutics for Up to $1.1 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArchimed to Buy Esperion Therapeutics for Up to $1.1 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-01 19:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Healthcare-focused investment firm Archimed is buying commercial-stage biopharmaceutical company Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for as much as $1.1 billion. \n</p>\n<p>\n  Esperion said Friday it has reached a definitive agreement that will see funds managed by Archimed pay shareholders $3.16 a share in cash, and offer the right to participate in milestone payments of up to $100 million tied to future sales performance. The upfront cash consideration represents a premium of 58% to Esperion's closing price a day earlier. \n</p>\n<p>\n  Esperion, which was founded in 2008, is focused on bringing new medicines to market and offers solutions to combat the risk of cardiovascular disease. \n</p>\n<p>\n  Chief Executive Sheldon Koenig said Archimed's acquisition offers Esperion shareholders with attractive and immediate upfront value while preserving the opportunity to see additional upside tied to future growth of the company's core cardiometabolic products. \n</p>\n<p>\n  Esperion's board unanimously approved the transaction and is recommending that shareholders vote their shares to approve the deal. \n</p>\n<p>\n  When the takeover is completed, Esperion will become a privately held company and its shares will no longer be listed on Nasdaq. The stock was halted in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 01, 2026 07:29 ET (11:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ESPR","symbol_name":"Esperion Therapeutics Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2632812611","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2632812611","pubTimestamp":1777634940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Healthcare-focused investment firm Archimed is buying commercial-stage biopharmaceutical company Esperion Therapeutics for as much as $1.1 billion.Esperion said Friday it has reached a definitive agreement that will see funds managed by Archimed pay shareholders $3.16 a share in cash, and offer the right to participate in milestone payments of up to $100 million tied to future sales performance. The upfront cash consideration represents a premium of 58% to Esperion's closing price a day earlier.Esperion, which was founded in 2008, is focused on bringing new medicines to market and offers solutions to combat the risk of cardiovascular disease.Chief Executive Sheldon Koenig said Archimed's acquisition offers Esperion shareholders with attractive and immediate upfront value while preserving the opportunity to see additional upside tied to future growth of the company's core cardiometabolic products.Esperion's board unanimously approved the transaction and is recommending that shareholders","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ESPR":"Esperion Therapeutics Inc.","BK4007":"制药"},"translate_title":"Archimed将以高达11亿美元收购Esperion Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":1.5},"content_text":"By Robb M. Stewart \n\n\n \n\n\n  Healthcare-focused investment firm Archimed is buying commercial-stage biopharmaceutical company Esperion Therapeutics for as much as $1.1 billion. \n\n\n  Esperion said Friday it has reached a definitive agreement that will see funds managed by Archimed pay shareholders $3.16 a share in cash, and offer the right to participate in milestone payments of up to $100 million tied to future sales performance. The upfront cash consideration represents a premium of 58% to Esperion's closing price a day earlier. \n\n\n  Esperion, which was founded in 2008, is focused on bringing new medicines to market and offers solutions to combat the risk of cardiovascular disease. \n\n\n  Chief Executive Sheldon Koenig said Archimed's acquisition offers Esperion shareholders with attractive and immediate upfront value while preserving the opportunity to see additional upside tied to future growth of the company's core cardiometabolic products. \n\n\n  Esperion's board unanimously approved the transaction and is recommending that shareholders vote their shares to approve the deal. \n\n\n  When the takeover is completed, Esperion will become a privately held company and its shares will no longer be listed on Nasdaq. The stock was halted in premarket trading. \n\n\n \n\n\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 01, 2026 07:29 ET (11:29 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}